Buprenorphine versus dihydrocodeine for opiate detoxification in primary care: a randomised controlled trial

Background Many drug users present to primary care requesting detoxification from illicit opiates. There are a number of detoxification agents but no recommended drug of choice. The purpose of this study is to compare buprenorphine with dihydrocodeine for detoxification from illicit opiates in primary care. Methods Open label randomised controlled trial in NHS Primary Care (General Practices), Leeds, UK. Sixty consenting adults using illicit opiates received either daily sublingual buprenorphine or daily oral dihydrocodeine. Reducing regimens for both interventions were at the discretion of prescribing doctor within a standard regimen of not more than 15 days. Primary outcome was abstinence from illicit opiates at final prescription as indicated by a urine sample. Secondary outcomes during detoxification period and at three and six months post detoxification were recorded. Results Only 23% completed the prescribed course of detoxification medication and gave a urine sample on collection of their final prescription. Risk of non-completion of detoxification was reduced if allocated buprenorphine (68% vs 88%, RR 0.58 CI 0.35–0.96, p = 0.065). A higher proportion of people allocated to buprenorphine provided a clean urine sample compared with those who received dihydrocodeine (21% vs 3%, RR 2.06 CI 1.33–3.21, p = 0.028). People allocated to buprenorphine had fewer visits to professional carers during detoxification and more were abstinent at three months (10 vs 4, RR 1.55 CI 0.96–2.52) and six months post detoxification (7 vs 3, RR 1.45 CI 0.84–2.49). Conclusion Informative randomised trials evaluating routine care within the primary care setting are possible amongst drug using populations. This small study generates unique data on commonly used treatment regimens

Coordination Properties of Klaeui's Tripodal Oxygen Donor toward Zirconium(IV)

The coordination properties of [(η5-C5H5)Co{PR2(O)}3]- (R = OEt (LOEt-), Et (LEt-)) toward Zr(IV) have been investigated and compared to related cyclopentadienyl complexes. Addition of 2 equiv of LOEt- to [ZrCl4(THF)2] yields labile [Zr(LOEt)2Cl2] (2), which undergoes Arbuzov dealkylation to yield a dinuclear, seven-coordinate complex 1. Reaction of 2 with MeLi yields the metathesis product LiLOEt. Addition of 2 equiv of AgOTos to 2 affords octahedral [Zr(LOEt)2](OTos)2 (3). Reaction of [ZrCpCl3] with LOEt- leads to Cp- displacement to give [ZrLOEtCl3] (4). Addition of 2 equiv of LEt- to [ZrCl4(THF)2] yields octahedral [Zr(LEt)2](Cl)2 (5). Compounds 1, 3, 4, and 5 have been characterized by X-ray crystallography